• OPEN AN ACCOUNT
Indian Indices
Sensex
80,238.85 -1,048.34
( -1.29%)
Global Indices
Nasdaq
48,904.78 -73.14
(-0.15%)
Dow Jones
6,863.50 -36.75
(-0.53%)
Hang Seng
56,282.78 -1,774.46
(-3.06%)
Nikkei 225
10,473.49 -306.62
(-2.84%)
Forex
USD-INR
91.06 0.13
(0.14%)
EUR-INR
107.55 0.22
(0.20%)
GBP-INR
122.70 -0.27
(-0.22%)
JPY-INR
0.58 0.00
(0.12%)

EQUITY - MARKET SCREENER

RattanIndia Enterprises Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
534597
INE834M01019
8.4574813
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
RTNINDIA
0
3797.09
EPS(TTM)
Face Value()
Div & Yield %
0
2
0
 

Zydus receives USFDA approval for Leuprolide Acetate injection
Nov 14,2025
Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Leuprolide Acetate injection, 14 mg/2.8 mL (1 mg/0.2 mL) multiple-dose vial (USRLD: Lupron Injection®, 1 mg/0.2 mL).

Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer.

Leuprolide Acetate injections will be manufactured at the Company's oncology injectable manufacturing facility at SEZ1, Ahmedabad (‘ALIDAC').

Leuprolide Acetate injection had annual sales of USD 69 mn in the United States (IQVIA MAT Sept 2025).